AC
PCRX icon

Avenir Corporation’s Pacira BioSciences PCRX Stock Holding History

Avenir Corporation’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,080
Closed -$987K – 67
2018
Q3 		$987K Hold
20,080
– – 0.11% 50
2018
Q2 		$644K Sell
20,080
-2,570
-11% -$88.7K 0.07% 53
2018
Q1 		$706K Buy
22,650
+6,780
+43% +$241K 0.08% 53
2017
Q4 		$724K Buy
15,870
+3,750
+31% +$149K 0.07% 55
2017
Q3 		$455K Buy
12,120
+2,100
+21% +$84.5K 0.04% 58
2017
Q2 		$478K Buy
10,020
+2,120
+27% +$98.4K 0.04% 58
2017
Q1 		$360K Hold
7,900
– – 0.03% 61
2016
Q4 		$255K Buy
7,900
+400
+5% +$13.3K 0.02% 64
2016
Q3 		$257K Buy
+7,500
New +$294K 0.02% 62
2016
Q1 		– Sell
-2,750
Closed -$211K – 69
2015
Q4 		$211K Buy
+2,750
New +$156K 0.02% 67

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return